← United States · Coverage record
US · SEC FORM 4
Alector, Inc.
ALEC · Nasdaq · CIK 0001653087 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
23 Form 4 transaction lines observed in the same window
9 sales · 14 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
Showing the six most active owners; 4 additional owner(s) remain in Form 4 evidence.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2020-02-03 · Wehner David M..
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.
Price performance
- 1M
- -32.5%
- 3M
- -5.4%
- 6M
- -23.9%
- 12M
- —
Volatility & liquidity
- Volatility
- 94.9%
- Beta
- —
- Avg daily value
- —
Valuation
- Market cap
- —
- P/E
- —
Fundamentals
- Profit margin
- -679.5%
- ROE
- -466.6%
- Industry
- Biotechnology
Market data
Price data up to: 2026-10-02 · Price source: OpenBB/yfinance · From SEC filings: Profit margin, ROE · Fiscal year ended: 2025-12-31 · Status: PASS
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 6,147,032
- Previous report
- 6,104,803
- Avg daily volume
- 1,072,911
- Days to cover
- 5.7
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2020-02-03 | Wehner David M. | Purchase (P) | Common Stock | 20,000 | USD 25.00 | USD 500,000 | SEC filing ↗ |
Form 4 evidence
40 transaction lines in the latest 365-day window; 367 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | Wong-Sarad Grace | Award / grant (A) | Common Stock | 55,555 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-10-14 | Rosenthal Arnon | Award / grant (A) | Common Stock | 217,500 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-10-14 | Berkley Neil Lindsay | Award / grant (A) | Common Stock | 44,567 | USD 0.00 | USD 0 | SEC filing ↗ |
Show recent Form 4 evidence (30 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | Wong-Sarad Grace | Award / grant (A) | Common Stock | 55,555 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-10-14 | Rosenthal Arnon | Award / grant (A) | Common Stock | 217,500 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-10-14 | Berkley Neil Lindsay | Award / grant (A) | Common Stock | 44,567 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-09-04 | Wong-Sarad Grace | Sale (S) | Common Stock | 3,625 | USD 2.51 | USD 9,099 | SEC filing ↗ |
| 2026-09-03 | Wong-Sarad Grace | Sale (S) | Common Stock | 5,165 | USD 2.67 | USD 13,791 | SEC filing ↗ |
| 2026-09-03 | Rosenthal Arnon | Sale (S) | Common Stock | 72,606 | USD 2.66 | USD 193,132 | SEC filing ↗ |
| 2026-09-03 | Berkley Neil Lindsay | Sale (S) | Common Stock | 29,251 | USD 2.66 | USD 77,808 | SEC filing ↗ |
| 2026-09-02 | Wong-Sarad Grace | Sale (S) | Common Stock | 656 | USD 2.75 | USD 1,804 | SEC filing ↗ |
| 2026-08-19 | Rosenthal Arnon | Gift (G) | Common Stock | 1,400,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-07-09 | Wong-Sarad Grace | Award / grant (A) | Common Stock | 20,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-17 | Yaffe Kristine | Award / grant (A) | Common Stock | 28,700 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-17 | SCHELLER RICHARD H | Award / grant (A) | Common Stock | 28,700 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-17 | LAVIGNE LOUIS J JR | Award / grant (A) | Common Stock | 28,700 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-17 | Hammond Paula | Award / grant (A) | Common Stock | 28,700 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-17 | GAROFALO ELIZABETH A. | Award / grant (A) | Common Stock | 28,700 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-17 | DESOUZA ERROL B | Award / grant (A) | Common Stock | 28,700 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-17 | Altmeyer Mark | Award / grant (A) | Common Stock | 28,700 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-03 | Wong-Sarad Grace | Sale (S) | Common Stock | 3,475 | USD 1.88 | USD 6,533 | SEC filing ↗ |
| 2026-06-02 | Wong-Sarad Grace | Sale (S) | Common Stock | 5,709 | USD 1.97 | USD 11,247 | SEC filing ↗ |
| 2026-06-02 | Rosenthal Arnon | Sale (S) | Common Stock | 87,216 | USD 1.97 | USD 171,816 | SEC filing ↗ |
| 2026-06-02 | Berkley Neil Lindsay | Sale (S) | Common Stock | 19,360 | USD 1.97 | USD 38,139 | SEC filing ↗ |
| 2026-06-01 | SCHELLER RICHARD H | Award / grant (A) | Common Stock | 10,833 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-16 | Wong-Sarad Grace | Sale (S) | Common Stock | 1,820 | USD 2.65 | USD 4,823 | SEC filing ↗ |
| 2026-03-15 | Berkley Neil Lindsay | Award / grant (A) | Common Stock | 54,600 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-03-13 | Rosenthal Arnon | Award / grant (A) | Common Stock | 116,246 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-03-10 | Wong-Sarad Grace | Sale (S) | Common Stock | 1,000 | USD 2.65 | USD 2,650 | SEC filing ↗ |
| 2026-03-03 | Wong-Sarad Grace | Sale (S) | Common Stock | 3,367 | USD 2.08 | USD 7,003 | SEC filing ↗ |
| 2026-03-02 | Wong-Sarad Grace | Sale (S) | Common Stock | 8,071 | USD 2.12 | USD 17,111 | SEC filing ↗ |
| 2026-03-02 | Rosenthal Arnon | Sale (S) | Common Stock | 81,864 | USD 2.12 | USD 173,552 | SEC filing ↗ |
| 2026-03-02 | Berkley Neil Lindsay | Sale (S) | Common Stock | 29,649 | USD 2.12 | USD 62,856 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | ALEC |
| CIK | 0001653087 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 367 transaction lines from 2020-01-09 to 2026-10-14 1 P purchase lines · 205 S sale lines · 161 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.